-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, AML, Anemias, apoptosis, autoimmune disorders, Biological, cell division, Diseases, Bone Marrow Failure, cell regulation, CMML, Combinations, Therapies, checkpoint inhibitors, MDS, Biological Processes, white blood cells, Immune Disorders, Technology and Procedures, Cell Lineage, cytogenetics, epigenetics, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, hematopoiesis, flow cytometry, immune mechanism, inflammation, molecular testing, NGS, pathogenesis, pathways, signal transduction
Monday, December 7, 2020: 7:00 AM-3:30 PM

Iván Martín, PhD1*, Eva Villamón, PhD2*, Rosario Abellán, PhD3*, Maria Jose Calasanz, PhD, BSc4,5,6,7,8,9,10*, Aroa Irigoyen, PhD11*, Guillermo F Sanz, MD, PhD12,13,14, Esperanza Such, PhD15*, Elvira Mora Casterá, MD16*, Míriam Gutiérrez, PhD17*, Rosa Collado, MD18*, Míriam Vara, PhD19*, Laura Blanco, MD20*, Itziar Oiartzabal, MD21*, Sara Álvarez, PhD22*, Teresa Bernal del Castillo, MD, PhD23,24,25*, Isabel Granada, PhD26,27*, Blanca Xicoy, MD28*, Lurdes Zamora, PhD29*, Andres Jerez, MD PhD30,31*, Raquel Fernández, PhD32*, Marisa Calabuig, MD33*, Francisca García34*, Alejandro Sanz, MD35*, Rosana Díez, MD36*, Ángela Gil, MD37*, Raquel de Paz, MD38*, Francisca López, MD39*, Teresa González, MD40*, Carlos Solano, MD, PhD34 and Mar Tormo, MD31,33,41

1Hematology Department, Hospital Clínico Universitario de Valencia. INCLIVA Research Institute. University of Valencia., VALENCIA, Spain
2Hematology department, Hospital Clínico Universitario de Valencia. INCLIVA Research Institute. University of Valencia., Valencia, Spain
3Biochemistry and Molecular Pathology Department., Hospital Clínico Universitario de Valencia. INCLIVA Research Institute., VALENCIA, Spain
4Servicio de Citogenética y de Genética Hematológica, Departamento de Genética, Universidad de Navarra, Pamplona, Spain
5Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain
6Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
7Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
8Scientific co-Director of CIMA LAB Diagnostics, CIMA Lab Diagnostics, University of Navarra, Pamplona, Spain
9Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
10Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain
11CIMA LAB Diagnostics. Universidad de Navarra., Pamplona, Spain
12CIBERONC, Instituto Carlos III, Madrid, Spain
13Hospital Universitario La Fe, Spanish MDS Cooperative Group, Valencia, Spain
14Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
15CIBERONC, Madrid, Spain
16Dept. of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
17Genetic Department. Hospital Universitario Infanta Sofía., Madrid, Spain
18Hematology Department., Hospital General Universitario, Valencia, Spain
19Hematology Department, Hospital Universitario de Cruces, Baracaldo, Spain
20Hematology Department., Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
21Hematology Department., Hospital Universitario Araba, Vitoria-Gasteiz, Spain
22NIMGenetics, Genómica y Medicina. Madrid, Madrid, Spain
23Hospital Universitario Central Asturias, ISPA, IUOPA, Oviedo, Spain
24Grupo Español de Síndromes Mielodisplásicos (GESMD), Oviedo, Spain
25Fundación General de la Universidad de Salamanca, Oviedo, ESP
26ICO-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Universitat Autònoma de Barcelona, Badalona, Spain
27CETLAM Group, Badalona, ESP
28Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol; Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
29Hematology Department, ICO - Hospital Germans Trias i Pujol, Badalona, Spain
30Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain, MURCIA, Spain
31Grupo Español de Síndromes Mielodisplásicos (GESMD), Valencia, Spain
32Oncohematological Cytogenetics Unit., Fundación Pública Galega de Medicina Xenómica., Santiago de Compostela, Spain
33Hospital Clínico Universitario de Valencia, Valencia, Spain
34Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
35Hematology Department., Hospital HM Sanchinarro, Madrid, Spain
36Hematology Department., Hospital Universitario Miguel Servet de Zaragoza., Zaragoza, Spain
37Hematology Department., Hospital Universitario de Guadalajara., Guadalajara, Spain
38Hematology Department, Hospital Universitario La Paz-Idipaz, Madrid, Spain
39Hematology Department., Hospital Arnau de Vilanova de Valencia, Valencia, Spain
40Hematology Department, Hospital Universitario de Salamanca., Salamanca, Spain
41Programa Español de Tratamientos en Hematologia, PETHEMA, Valencia, Spain

Sunisa Kongkiatkamon, MD1,2*, Samuel Li, BA3*, Tatiana Dombrovski4*, Laila Terkawi2*, Cassandra M Kerr, MS5*, Vera Adema, PhD2*, Yasunobu Nagata, MD, PhD6*, Wencke Walter, PhD7*, Hassan Awada, MD5*, Bartlomiej Przychodzen8*, Stephan Hutter, PhD7*, Carmelo Gurnari, MD8*, Simona Pagliuca, MD2, Manja Meggendorfer, PhD9, Claudia Haferlach, MD10, Valeria Visconte, PhD2, Torsten Haferlach, MD11, Jaroslaw P. Maciejewski, MD, PhD5 and Thomas LaFramboise, Ph.D.4*

1Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH
4Department of Genetics and Genome Sciences Case Western Reserve University School of Medicine, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Cleveland, Ohio
7MLL Munich Leukemia Laboratory, Munich, Germany
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland
9MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany
10MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany
11MLL Munchner Leukamie Labor Gmbh, Munchen, Germany

Sung-Eun Lee, M.D, Ph.D.1,2*, Feng Wang, PhD3*, Abel Trujillo-Ocampo, PhD, MS1, Wilfredo Ruiz Vazquez1*, Hyun-Woo Cho1*, Koichi Takahashi, MD, PhD3,4, Gheath Alatrash1,5, Jeffrey J. Molldrem1,5, Richard E. Champlin, MD6, Naval Daver, MD7, Hagop M. Kantarjian, MD8, P. Andrew Futreal9*, Guillermo Garcia-Manero, MD10 and Jin S. Im5,11

1Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Hematopoietic Biology and Malignancy, Division of Cancer Medicine, The University of Texas M.D, Anderson Cancer Center, Houston, TX
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
8University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Genomic Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
11Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Marion Strullu, MD1*, Aurélie Caye-Eude, PharmD, PhD1,2*, Loïc Maillard, PhD1*, Chloé Arfeuille, MD1,2*, Elodie Lainey, PharmD, PhD1*, Florian Piques, MD2*, Odile Fenneteau, PharmD3*, Bruno Cassinat, PharmD, PhD1,4*, Fabien Guimiot, PhD5*, Jean-Hugues Dalle, MD, PhD6,7*, André Baruchel8, Christine Chomienne, MD, PhD1,9, Dominique Bonnet, PhD10, Michele Souyri, PhD1* and Hélène Cavé, PharmD, PhD1,2*

1Institut de Recherche St Louis, Université de Paris, INSERM U1131, Paris, France
2Département de Génétique, APHP, Hôpital Robert Debré, Paris, France
3Laboratoire d’Hématologie, APHP, Hôpital Robert Debré,, Paris, France
4Université de Paris, Cellular biology Department, Saint-Louis hospital, APHP, Paris, France
5Unité de Foeto-pathologie, APHP, Hôpital Robert Debré, Paris, France
6University of Paris, Paris, France
7APHP, Robert Debré Hospital, Paris, France
8Pediatric Hematology-Immunology Department, APHP, Robert Debré Hospital, Paris, France
9Unité de Biologie cellulaire, Université de Paris, Paris, France
10Hematopoietic Stem Cell lab, The Francis Crick Institute, London, United Kingdom

Carolin Brings1*, Ron-Patrick Cadeddu, PhD1*, Julia Fröbel, PhD1,2*, Hubert Schelzig, MD3*, Rainer Haas, MD1* and Norbert Gattermann, MD4

1Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
2Immunology, Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut (FLI), Jena, Germany
3Dept. of Vascular and Endovascular Surgery, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
4Dept. of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-Universitat, Dusseldorf, Germany

Matilde Y Follo, PhD1*, Sara Mongiorgi, PhD1*, Alessia De Stefano, BSc1*, Valentina Indio, PhD2*, Annalisa Astolfi, PhD2,3*, Andrea Pellagatti4*, Stefano Ratti, MD1*, Miriam Fogli, PhD5*, Sarah Parisi, MD, PhD5, Andrea Pession6*, Michele Cavo5*, Lucia Manzoli, MD1*, Lucio Cocco, MD1*, Jacqueline Boultwood4 and Carlo Finelli7*

1Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
2Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
3Dipartimento di Morfologia, chirurgia e medicina sperimentale, University of Ferrara, Ferrara, Italy
4Bloodwise Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
5Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy
6Sant'Orsola-Malpighi Hospital, "Lalla Seràgnoli" Institute, Bologna, Italy
7Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy

Christina Ganster1, Lea Naomi Eder1*, Katayoon Shirneshan1*, Katharina Rittscher1*, Paolo Mazzeo1*, Roxana Schaab1*, Ahmet H. Elmaagacli, Prof, MD, PhD2*, Uwe Platzbecker, MD3, Bertram Glass4*, Ulrich Germing5*, Maria Kamper1*, Elzbieta Barbara Brzuszkiewicz1* and Detlef Haase, MD1*

1Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
2Department of Hematology and Stem Cell Transplantation, Asklepios Clinic St. Georg, Hamburg, Hamburg, Germany
3Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
4Clinic for Hematology, Oncology, Tumorimmunology and Palliative Care, Helios Clinic Berlin-Buch, Berlin, Germany
5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Faculty of Medicine, Düsseldorf, Germany

Hassan Awada, MD1, Cassandra M. Kerr, MS2*, Vera Adema, PhD2*, Carmelo Gurnari, MD3*, Simona Pagliuca, MD1, Heesun J. Rogers, MD, PhD4, Hetty E. Carraway, MD, MBA5, Mikkael A. Sekeres, MD, MS6, Jaroslaw P. Maciejewski, MD, PhD2 and Valeria Visconte, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland, OH
4Department of Hematopathology, Cleveland Clinic, Cleveland
5Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Jonathan Feld, MD1, Jane Houldsworth, PhD2, Asha Reddy, MS2*, Zinnia Mai, BS2*, Shafinaz Hussein, MD2*, Shyamala C. Navada, MD1, Lewis R. Silverman, MD1 and Meenakshi Mehrotra, PhD2*

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Pathology, Mount Sinai Hospital, New York, NY

*signifies non-member of ASH